The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.

Abstract

TWO VARIANTS OF THE INOSINE TRIPHOSPHATASE (ITPA:

rs1127354, rs7270101) gene cause ITPA deficiency and protect against the hemolytic toxicity of ribavirin. We investigated the clinical significance of ITPA variants in Korean patients treated with pegylated interferon (PEG-IFN) plus ribavirin. Of the 133 patients, 108 were CC and 25 were non-CC at rs1127354 (groups A and B, respectively). On the other hand, at rs7270101 all 133 were AA. The mean values of Hemoglobin (Hgb) after 4, 8, and 12 weeks of treatment in groups A and B were 12.2 and 14.0, 11.8 and 13.2, and 11.5 and 12.9, respectively (P=0.001, 0.036, 0.036). Sustained virologic response (SVR) was achieved in 67.8% (40/59) of genotype 1 patients and in 75% (27/36) of non-genotype 1 patients. Regarding ITPA variants, SVR was achieved by 66% and 80% of genotype 1 (P=0.282), and by 78% and 71% (P=0.726) of non-genotype 1. SVR was not significantly different in groups A and B. In conclusion, non-CC at rs1127354 without involvement of rs7270101 is strongly associated with protection from ribavirin-induced anemia, however, ITPA genotype is not associated with SVR.

• Authors: Ju Seung Kim, Sung-Min Ahn, Young Kul Jung, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
• Journal: Journal of Korean medical science (J Korean Med Sci) Vol. 28 Issue 8 Pg. 1213-9 (Aug 2013) ISSN: 1598-6357 [Electronic] Korea (South)
• PMID: 23960450 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Hemoglobins
• IFNL3 protein, human
• Interferon-alpha
• Interleukins
• Recombinant Proteins
• Polyethylene Glycols
• Ribavirin
• Interferons
• Pyrophosphatases
• inosine triphosphatase
• peginterferon alfa-2a

Topics

• Adult
• Alleles
• Antiviral Agents (therapeutic use)
• Asian People (genetics)
• Cohort Studies
• Drug Therapy, Combination
• Female
• Genotype
• Hemoglobins (analysis)
• Hemolysis
• Hepacivirus (genetics)
• Hepatitis C, Chronic (drug therapy, genetics)
• Humans
• Interferon-alpha (therapeutic use)
• Interferons
• Interleukins (genetics)
• Male
• Middle Aged
• Polyethylene Glycols (therapeutic use)
• Pyrophosphatases (genetics)
• Recombinant Proteins (therapeutic use)
• Republic of Korea
• Retrospective Studies
• Ribavirin (therapeutic use)
• Treatment Outcome